醫療器械股逆勢上漲 九安醫療、尚榮醫療等多股漲停
格隆匯3月6日丨A股三大指數繼續處於下跌中,但醫療器械股逆勢上漲。其中,九安醫療、尚榮醫療、理邦儀器漲停,南衞股份、振德醫療漲超7%,開立醫療、陽普醫療和三鑫醫療等均漲超6%。中共中央、國務院日前印發了《關於深化醫療保障制度改革的意見》,研究提出了“1+4+2”的總體改革框架。“1”是力爭到2030年,全面建成以基本醫療保險為主體,醫療救助為託底,補充醫療保險、商業健康保險、慈善捐贈、醫療互助共同發展的多層次醫療保障制度體系。“4”是健全待遇保障、籌資運行、醫保支付、基金監管四個機制。“2”是完善醫藥服務供給和醫療保障服務兩個支撐。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.